首页 | 本学科首页   官方微博 | 高级检索  
按 检索        


Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
Authors:Myriam Sasanelli  Michel Meignan  Corinne Haioun  Alina Berriolo-Riedinger  René-Olivier Casasnovas  Alberto Biggi  Andrea Gallamini  Barry A Siegel  Amanda F Cashen  Pierre Véra  Hervé Tilly  Annibale Versari  Emmanuel Itti
Institution:1. Nuclear Medicine and Lymphoid Malignancies Unit, Henri Mondor Hospital, Paris-Est University, 51 Ave. du Mal de Lattre, 94010, Créteil, France
2. Nuclear Medicine and Hematology, Georges-Fran?ois Leclerc Center, Le Bocage Hospital, Dijon, France
3. Nuclear Medicine and Hematology, Santa Croce e Carle Hospital, Cuneo, Italy
4. Nuclear Medicine and Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA
5. Nuclear Medicine and Hematology, Henri Becquerel Center, Rouen, France
6. Nuclear Medicine, Santa Maria Nuova Hospital-IRCCS, Reggio Emilia, Italy
Abstract:

Purpose

We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL).

Methods

TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent 18F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41 % using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).

Results

Median follow-up was 39 months. Average pretherapy TMTV was 509?±?568 cm3. The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm3) and 60 % in the high metabolic burden group (TMTV >550 cm3, p?=?0.04), and prediction of OS was even better (87 % vs. 60 %, p?=?0.0003). Cox regression showed independence of TMTV for OS prediction (p?=?0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index.

Conclusion

Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
Keywords:
本文献已被 SpringerLink 等数据库收录！
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号